[Cytostatic primary therapy of squamous cell carcinoma of the oro- and hypopharynx with cisplatin, bleomycin and methotrexate].
This is a report on induction chemotherapy of 20 oropharyngeal and 20 hypopharyngeal squamous cell carcinomas with cis-platinum, bleomycin, and methotrexate. The response rate, defined as a tumour regression of at least 50%, was 70% for the hypopharynx and 80% for the oropharynx. The lymph nodes responded in 50% of the cases. The toxicity was low. Induction chemotherapy is considered to be significant, but it must be stressed that surgery and/or radiation therapy must follow to sustain the initial success.
T
T
Deitmer
D
D
Urbanitz
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010610:Pharyngeal Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D002945:Cisplatin; D008727:Methotrexate
Zytostatische Primärtherapie von Plattenepithel-Karzinomen des Oro- und Hypopharynx mit Cisplatin, Bleomycin und Methotrexat.